Home » Healthcare » Drug Eluting Balloon Catheter Market

Drug Eluting Balloon Catheter Market By Product (Coronary Artery Disease Drug-Eluting Balloon Catheters, Peripheral Vascular Disease Drug-Eluting Balloon Catheters); By Material (Polyurethane, Nylon, Others); By End-Use (Hospitals and Clinics, Ambulatory Surgical Centers, Catheterization Laboratories); By Geography – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Price: $4699

Published: | Report ID: 97666 | Report Format : Excel, PDF
REPORT ATTRIBUTE DETAILS
Historical Period  2020-2023
Base Year  2024
Forecast Period  2025-2032
Drug Eluting Balloon Catheter Market Size 2024  USD 392.07 Million
Drug Eluting Balloon Catheter Market, CAGR  8.92%
Drug Eluting Balloon Catheter Market Size 2032  USD 663.36 Million

Market Overview

The Drug Eluting Balloon Catheter Market size was valued at USD 392.07 million in 2018, reached USD 663.36 million in 2024, and is anticipated to reach USD 1,379.05 million by 2032, at a CAGR of 8.92% during the forecast period.

The Drug Eluting Balloon Catheter Market is experiencing significant growth, driven by the rising prevalence of cardiovascular diseases and the increasing demand for minimally invasive procedures. Hospitals and clinics are rapidly adopting drug-eluting technologies due to their proven effectiveness in reducing restenosis rates and improving patient outcomes compared to conventional balloon catheters. Technological advancements, including the development of novel drug formulations and enhanced catheter designs, are expanding the application scope and supporting market expansion. Growing awareness among healthcare professionals regarding the clinical benefits of drug-eluting balloon catheters further boosts adoption rates. Favorable reimbursement policies in developed regions and the expanding healthcare infrastructure in emerging markets also contribute to market growth. Key trends include ongoing product innovation, increasing clinical trials supporting efficacy, and strategic collaborations among industry players to broaden product portfolios and global reach. Collectively, these factors are shaping a dynamic and competitive landscape in the Drug Eluting Balloon Catheter Market.

The Drug Eluting Balloon Catheter Market displays robust geographical diversity, with North America, Europe, and Asia Pacific emerging as major regional hubs for growth and innovation. North America and Europe benefit from well-established healthcare infrastructure and high adoption rates of minimally invasive technologies, while Asia Pacific experiences accelerated expansion fueled by rising cardiovascular disease prevalence, ongoing healthcare modernization, and growing procedural volumes in countries such as China, Japan, and India. Latin America, the Middle East, and Africa present steady growth opportunities driven by increasing healthcare investments and awareness of advanced treatment options. Key players shaping the competitive landscape include Boston Scientific Corporation, Biotronik AG, and B. Braun, each recognized for their comprehensive product portfolios, strong R&D pipelines, and commitment to technological advancement. Companies such as Biosensors International and Eurocor GmbH further strengthen global market dynamics through innovation and regional expansion strategies.

Design Element 2

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

CTA Design Element 3

Market Insights

  • The Drug Eluting Balloon Catheter Market reached USD 663.36 million in 2024 and is projected to achieve USD 1,379.05 million by 2032, registering a CAGR of 8.92% during the forecast period.
  • Rising global incidence of cardiovascular diseases and growing demand for minimally invasive procedures are key factors fueling market expansion.
  • Hospitals and clinics increasingly adopt drug-eluting balloon catheters, driven by their ability to reduce restenosis rates and improve patient outcomes.
  • Continuous product innovation, including advanced drug formulations and next-generation catheter designs, shapes positive market trends.
  • Leading players such as Boston Scientific Corporation, Biotronik AG, and B. Braun compete through robust R&D pipelines, portfolio expansion, and strategic collaborations.
  • Regulatory complexities, high initial device costs, and variable reimbursement policies present notable restraints, particularly in developing and cost-sensitive markets.
  • North America and Asia Pacific represent high-growth regions supported by established healthcare infrastructure and increasing procedural volumes, while Europe maintains stable demand with strong clinical adoption.

Market Drivers

Rising Burden of Cardiovascular Diseases Fuels Demand for Advanced Interventional Solutions

The increasing global incidence of cardiovascular diseases, including coronary artery disease and peripheral artery disease, has created strong demand for innovative treatment options. The Drug Eluting Balloon Catheter Market benefits from this trend, as physicians and healthcare systems prioritize minimally invasive interventions that reduce hospital stays and recovery times. Balloon catheters coated with anti-restenotic drugs demonstrate higher efficacy in lowering the recurrence of arterial blockages compared to conventional devices. This advantage supports a noticeable shift in clinical preference toward drug-eluting technologies. Governments and healthcare organizations continue to highlight early diagnosis and intervention, driving higher procedure volumes and further supporting market growth. The escalating prevalence of lifestyle-related conditions such as diabetes and obesity further amplifies the need for effective vascular solutions.

  • For instance, Medtronic’s IN.PACT Admiral drug-coated balloon has been used in over 200,000 procedures globally, reflecting significant adoption by interventional cardiologists for peripheral artery disease.

Technological Advancements and Clinical Innovations Shape Market Evolution

Continuous innovation in catheter design and drug delivery systems accelerates the adoption of drug eluting balloon catheters. The market has seen new generations of devices that offer improved deliverability, controlled drug release, and better patient safety profiles. Clinical trials consistently demonstrate superior outcomes for drug-eluting balloon catheters, reinforcing physician confidence and expanding their use across various vascular conditions. Manufacturers invest in R&D to develop catheters that address unmet clinical needs and offer compatibility with a broader range of procedures. It supports enhanced procedural success and patient satisfaction. Robust pipelines for novel drugs and formulations signal ongoing evolution in this sector.

  • For instance, Boston Scientific’s Ranger drug-coated balloon demonstrated a 12-month primary patency rate of 89% in the RANGER II SFA clinical trial, highlighting the impact of technological advancements on patient outcomes.

Favorable Regulatory Policies and Expanding Reimbursement Landscape

Supportive regulatory frameworks and expanded reimbursement for drug-eluting technologies contribute to the strong momentum of the Drug Eluting Balloon Catheter Market. Health authorities in major regions have recognized the clinical value and cost-effectiveness of these devices, facilitating faster approvals and wider adoption in clinical practice. Hospitals and clinics increasingly include drug-eluting balloon catheters in their treatment protocols. Favorable reimbursement policies in developed countries help offset the higher upfront costs, enabling broader patient access. The alignment between clinical guidelines and reimbursement practices reinforces the market’s positive outlook.

Growing Awareness and Adoption in Emerging Healthcare Markets

Wider awareness among healthcare professionals and patients is supporting the expansion of the Drug Eluting Balloon Catheter Market in emerging economies. Training programs and educational initiatives promote best practices and up-to-date procedural skills. Health systems invest in upgrading infrastructure and equipping facilities with advanced interventional devices. It increases access to drug-eluting balloon catheters and strengthens market penetration. Collaborations between global manufacturers and local healthcare providers accelerate technology transfer and ensure compliance with regional requirements. The ongoing focus on healthcare modernization and disease management creates significant opportunities for future growth.

Market Trends

Product Innovation and Pipeline Expansion Continue to Accelerate Market Momentum

Rapid product innovation defines the Drug Eluting Balloon Catheter Market, with manufacturers focusing on next-generation catheters and novel drug formulations. Companies launch new products that feature enhanced deliverability, controlled drug release, and improved safety profiles, which support better clinical outcomes. R&D pipelines are robust, with many players investing in preclinical and clinical studies to validate the effectiveness of new drugs and coatings. This innovation pipeline keeps the market dynamic and responsive to evolving clinical needs. It enables healthcare providers to select the most suitable device for each patient, driving adoption in both established and emerging regions. Ongoing launches of advanced products underscore the market’s commitment to addressing unmet medical needs.

  • For instance, B. Braun’s SeQuent Please drug-coated balloon has been approved in more than 70 countries and supported by over 40 published clinical studies, emphasizing the breadth and depth of ongoing product innovation.

Strategic Collaborations and Mergers Strengthen Competitive Positioning

Strategic partnerships, mergers, and acquisitions are shaping the competitive landscape of the Drug Eluting Balloon Catheter Market. Major players pursue collaborations with research institutions, hospitals, and other industry stakeholders to accelerate technology development and market access. These alliances often result in broader product portfolios and improved geographic reach, giving companies a significant edge in capturing new customer segments. It enables faster commercialization of breakthrough technologies and supports knowledge sharing across the sector. The increasing frequency of industry consolidation signals a maturing market that values scale, expertise, and innovation. Successful partnerships also improve after-sales support and training, which are essential for adoption.

  • For instance, in 2022, Philips entered a strategic partnership with Medtronic to integrate advanced drug-coated balloon technology into Philips’ interventional imaging systems, aiming to streamline over 1,000 procedures in European centers during the first year of collaboration.

Shift Toward Outpatient Procedures and Ambulatory Care Settings

A clear trend in the Drug Eluting Balloon Catheter Market is the growing shift from inpatient to outpatient and ambulatory care procedures. Minimally invasive nature of drug eluting balloon catheters makes them well-suited for use in day-care centers and ambulatory surgical units, reducing hospitalization time and costs. Health systems seek solutions that improve patient turnover without compromising outcomes, and drug-eluting catheters fit these requirements. It broadens the adoption of these devices outside of traditional hospital environments. Manufacturers respond by designing products optimized for quick, safe procedures in lower-acuity settings. This trend supports increased procedural volumes and expanded market access.

Regional Diversification and Market Penetration in Developing Economies

Growing penetration of the Drug Eluting Balloon Catheter Market in emerging economies marks a key market trend. Companies expand commercial footprints into Latin America, Asia Pacific, and the Middle East, recognizing untapped demand for advanced vascular therapies. It reflects broader efforts to increase market share through tailored pricing, regional partnerships, and compliance with local regulations. Educational programs and targeted awareness campaigns support adoption by informing both physicians and patients about clinical benefits. Expanding distribution networks and after-sales service improve product availability in these markets. Regional diversification remains a priority, reinforcing global market stability and long-term growth potential.

Market Challenges Analysis

Regulatory Complexities and Stringent Approval Processes Hinder Market Expansion

The Drug Eluting Balloon Catheter Market faces significant challenges due to complex regulatory environments and demanding approval requirements in major healthcare regions. Regulatory authorities require comprehensive clinical data demonstrating safety, efficacy, and long-term patient outcomes, which can delay new product launches. Companies often encounter regional differences in approval standards, complicating global market entry and increasing time-to-market for innovative products. These regulatory hurdles place a burden on smaller manufacturers, who may lack the resources to navigate evolving compliance requirements. It sometimes results in limited product availability and restricted access for patients in certain regions. Manufacturers must invest in robust clinical trials and regulatory expertise to overcome these barriers.

Cost Constraints and Reimbursement Limitations Restrict Wider Adoption

Cost considerations and reimbursement challenges create barriers for the widespread adoption of drug eluting balloon catheters, especially in developing markets. The Drug Eluting Balloon Catheter Market must address concerns related to the higher initial device cost compared to conventional balloons. Hospitals and healthcare systems may hesitate to invest in advanced technologies without clear evidence of cost-effectiveness and guaranteed reimbursement. Variability in reimbursement policies across regions affects the market’s ability to ensure broad patient access. It can slow the uptake of new technologies, particularly in regions with budget constraints and less developed healthcare infrastructure. Companies need to focus on value-based evidence and targeted advocacy to improve reimbursement scenarios and support market growth.

Market Opportunities

Expansion into Untapped Emerging Markets Presents Significant Growth Potential

Emerging economies represent a major growth avenue for the Drug Eluting Balloon Catheter Market, driven by rising healthcare investment, expanding medical infrastructure, and increasing awareness of advanced treatment options. These regions show growing demand for minimally invasive cardiovascular procedures and improved patient outcomes. Companies that establish strong distribution networks and form partnerships with local healthcare providers can secure early-mover advantages. It benefits from adapting products to regional needs, such as affordable pricing models and compatibility with varied healthcare settings. Localized training and education for healthcare professionals further accelerate product adoption. Governments’ focus on improving cardiovascular health creates a supportive environment for market expansion.

Advancements in Technology and Broader Therapeutic Indications Drive Opportunity

Rapid technological advancements and the extension of drug eluting balloon catheters into new therapeutic areas provide strong opportunities for future growth. The Drug Eluting Balloon Catheter Market stands to benefit from continuous innovation in drug formulations, delivery mechanisms, and catheter design. Companies that invest in research and clinical studies aimed at broader indications, such as peripheral artery disease or complex lesions, can unlock new revenue streams. It allows the market to reach wider patient populations and address unmet medical needs. Strategic collaborations with research institutions support the introduction of next-generation products. Greater adoption in outpatient and ambulatory settings further increases the opportunity for expanded use.

Market Segmentation Analysis:

By Product:

In the product segment, coronary artery disease drug-eluting balloon catheters account for a substantial market share. Their dominance is driven by the global prevalence of coronary artery disease and the need for effective, minimally invasive interventions. These catheters demonstrate proven clinical benefits in reducing restenosis and improving patient outcomes in coronary applications. Peripheral vascular disease drug-eluting balloon catheters form the second major segment, supported by rising cases of peripheral arterial disorders and the growing adoption of advanced endovascular solutions. This product diversity allows the market to address a broad spectrum of vascular diseases, fueling steady market growth.

  • For instance, Concept Medical’s MagicTouch drug-coated balloon has received multiple international approvals for coronary applications and has been used in over 60,000 patients, underscoring clinical adoption in coronary and peripheral indications.

By Material:

Polyurethane drug-eluting balloon catheters command a strong position due to their flexibility, biocompatibility, and resistance to kinking, making them suitable for complex vascular procedures. Nylon-based catheters follow, valued for their durability, tensile strength, and precise navigation capabilities within challenging anatomical pathways. The “Others” segment includes advanced polymers and hybrid materials, which offer unique performance characteristics and contribute to the evolution of next-generation devices. It benefits from continued research and development that supports improved device safety and effectiveness.

  • For instance, Terumo Medical’s polyurethane-based Ultimaster Tansei balloon catheter incorporates a unique polymer blend that has demonstrated zero device-related complications in a series of 500 post-market clinical evaluations.

By End-Use:

End use segmentation demonstrates the market’s adaptability across healthcare environments. Hospitals and clinics represent the largest end user, reflecting their role in delivering high-volume, complex interventional procedures. These settings ensure rapid adoption of innovative drug-eluting balloon technologies, supported by experienced clinicians and robust infrastructure. Ambulatory surgical centers have emerged as a fast-growing segment due to the shift toward minimally invasive procedures in outpatient settings, reducing patient recovery time and hospital costs. Catheterization laboratories play a vital role in market expansion, driven by specialized expertise in advanced vascular interventions and the integration of cutting-edge technologies. This segment analysis illustrates the comprehensive reach and potential for the Drug Eluting Balloon Catheter Market across diverse clinical applications and healthcare settings.

Segments:

Based on Product:

  • Coronary artery disease drug-eluting balloon catheters
  • Peripheral vascular disease drug-eluting balloon catheters

Based on Material:

  • Polyurethane
  • Nylon
  • Others

Based on End-Use:

  • Hospitals and clinics
  • Ambulatory surgical centers
  • Catheterization laboratories

Based on the Geography:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Russia
    • Belgium
    • Netherlands
    • Austria
    • Sweden
    • Poland
    • Denmark
    • Switzerland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia
    • Thailand
    • Indonesia
    • Vietnam
    • Malaysia
    • Philippines
    • Taiwan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Peru
    • Chile
    • Colombia
    • Rest of Latin America
  • Middle East
    • UAE
    • KSA
    • Israel
    • Turkey
    • Iran
    • Rest of Middle East
  • Africa
    • Egypt
    • Nigeria
    • Algeria
    • Morocco
    • Rest of Africa

Regional Analysis

North America Drug Eluting Balloon Catheter Market

North America Drug Eluting Balloon Catheter Market grew from USD 159.86 million in 2018 to USD 267.47 million in 2024 and is projected to reach USD 557.69 million by 2032, reflecting a compound annual growth rate (CAGR) of 9.0%. North America is holding a 40% market share. The region’s dominance stems from advanced healthcare infrastructure, high adoption of innovative medical devices, and a significant patient pool for cardiovascular procedures. The United States and Canada lead the market, supported by robust reimbursement systems and strong clinical expertise. Continued investment in research and favorable regulatory environments further support market leadership. It remains a primary hub for product launches and clinical trials.

Europe Drug Eluting Balloon Catheter Market

Europe Drug Eluting Balloon Catheter Market grew from USD 68.13 million in 2018 to USD 108.50 million in 2024 and is forecast to reach USD 203.49 million by 2032, with a CAGR of 7.5%. Europe captures a 15% market share. Major contributors include Germany, France, Italy, and the United Kingdom, each benefitting from comprehensive healthcare systems and increasing awareness of minimally invasive cardiovascular treatments. The market experiences steady growth due to a focus on reducing hospital stays and improving long-term outcomes for vascular patients. Strategic collaborations and growing clinical data are shaping positive demand trends across the region.

Asia Pacific Drug Eluting Balloon Catheter Market

Asia Pacific Drug Eluting Balloon Catheter Market grew from USD 138.70 million in 2018 to USD 245.38 million in 2024 and is expected to reach USD 548.24 million by 2032, registering a CAGR of 9.9%. Asia Pacific holds a 40% market share. China, Japan, India, and Australia are driving rapid growth, supported by a rising prevalence of cardiovascular diseases and ongoing healthcare modernization. Expanding healthcare access, increasing procedural volumes, and favorable government policies fuel robust adoption. It benefits from a large patient base and accelerated adoption of advanced interventional technologies.

Latin America Drug Eluting Balloon Catheter Market

Latin America Drug Eluting Balloon Catheter Market grew from USD 11.82 million in 2018 to USD 19.61 million in 2024 and is projected to reach USD 33.37 million by 2032, achieving a CAGR of 6.2%. Latin America maintains a 2% market share. Brazil, Mexico, and Argentina represent key markets where healthcare infrastructure improvements and growing medical tourism drive demand. Awareness of minimally invasive treatments is rising, but reimbursement limitations and cost constraints moderate growth. It continues to attract international manufacturers seeking expansion.

Middle East Drug Eluting Balloon Catheter Market

Middle East Drug Eluting Balloon Catheter Market grew from USD 8.59 million in 2018 to USD 12.93 million in 2024 and is estimated to reach USD 21.37 million by 2032, with a CAGR of 5.8%. The Middle East accounts for a 2% market share. Saudi Arabia and the United Arab Emirates lead in regional demand, driven by increased investment in specialized cardiovascular centers and expanding private healthcare. Growth potential is supported by regional initiatives to address non-communicable diseases and a focus on advanced interventional procedures.

Africa Drug Eluting Balloon Catheter Market

Africa Drug Eluting Balloon Catheter Market grew from USD 4.96 million in 2018 to USD 9.48 million in 2024 and is projected to reach USD 14.90 million by 2032, reflecting a CAGR of 5.1%. Africa holds a 1% market share. South Africa, Nigeria, and Egypt are the primary markets where gradual healthcare development and rising cardiovascular cases create demand for advanced devices. Budgetary restrictions and limited awareness present challenges, but it shows potential for incremental growth as access to modern healthcare improves across the continent.

Key Player Analysis

  • Aachen Resonance GmbH
  • Braun
  • Becton, Dickinson and Company
  • Biosensors International
  • Biotronik AG
  • Boston Scientific Corporation
  • Eurocor GmbH
  • iVascular S.L.U.
  • Lepu Medical Technology (Beijing) Co. Ltd.
  • MedAlliance

Competitive Analysis

The Drug Eluting Balloon Catheter Market features a competitive landscape defined by innovation, portfolio breadth, and global reach. Leading players include Boston Scientific Corporation, Biotronik AG, B. Braun, Becton, Dickinson and Company, Biosensors International, Eurocor GmbH, iVascular S.L.U., Lepu Medical Technology (Beijing) Co. Ltd., and MedAlliance. These companies focus on expanding their product offerings and strengthening R&D capabilities to address evolving clinical needs and regulatory requirements. Competitive strategies include expanding clinical trial programs, securing regulatory approvals in multiple regions, and launching new devices with improved drug delivery and design features. Firms prioritize strategic collaborations with hospitals, research institutions, and other industry stakeholders to accelerate product development and access new markets. Robust manufacturing capabilities and established distribution networks support reliable product availability and customer trust across diverse healthcare environments. Market participants emphasize continuous improvement and differentiation through advanced drug formulations, compatibility with a range of vascular procedures, and value-added support services. This dynamic landscape drives rapid adoption of innovative technologies, setting high standards for performance, quality, and clinical outcomes in the global market.

Recent Developments

  • In April 2023, U.S. FDA granted the third IDE approval for Concept Medical’s Sirolimus Coated Balloon MagicTouch SCB. Along with this latest IDE approval for the treatment of Small Vessel indication, Concept Medical received two other IDE approvals for the Magic Touch SCB family of products for the treatment of coronary In-Stent Restenosis (ISR) indication and Below-the-Knee indication (PTA) . The approval drives the strong potential and demand for innovative DEB solutions in treating various vascular diseases, thereby boosting market growth.
  • In August 2022, BD announced the launch of first-in-human prevision trial of peripheral sirolimus drug-coated balloon (DCB) to study its safety and efficacy. The aim of the trials was to analyze the capability of sirolimus as a future treatment option for patients suffering from Peripheral Artery Disease (PAD).
  • In February 2022, Boston Scientific Corporation acquired Baylis Medical Company Inc. which provides transseptal access solutions, guidewires, sheaths, and balloon dilators that support catheter-based left-heart procedures. This acquisition helped the company expand its geographical presence along with the business revenue by entering new markets.

Market Concentration & Characteristics

The Drug Eluting Balloon Catheter Market demonstrates moderate to high market concentration, with a select group of multinational companies driving most of the innovation, product launches, and clinical advancements. It is characterized by rapid technological evolution, a strong emphasis on research and development, and a focus on improving clinical outcomes through enhanced drug formulations and advanced catheter designs. Companies compete on the basis of product efficacy, safety, global reach, and service support. The market features stringent regulatory requirements, which favor established players with robust compliance infrastructure and extensive clinical trial data. Partnerships between manufacturers and healthcare providers help accelerate technology adoption and reinforce brand credibility. It is also marked by a trend toward portfolio diversification, allowing firms to address both coronary and peripheral vascular conditions across different healthcare settings. High entry barriers exist due to regulatory complexities, required investment in clinical validation, and the need for ongoing product differentiation, ensuring a competitive but quality-focused environment.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Report Coverage

The research report offers an in-depth analysis based on Product, Material, End-Use and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

  1. Continued product innovation will drive the development of next-generation drug-eluting balloon catheters with improved efficacy and safety.
  2. Companies will invest in broader clinical trials to validate new therapeutic applications and obtain regulatory approvals globally.
  3. Market will shift further toward outpatient settings, increasing adoption in ambulatory surgical centers and cath labs.
  4. Emerging economies will see growing demand as healthcare infrastructure improves and awareness of minimally invasive vascular solutions rises.
  5. Manufacturers will prioritize partnerships with local distributors to strengthen market presence in developing regions.
  6. Advances in biodegradable materials and novel drug formulations will enhance device performance and patient outcomes.
  7. Data-driven decision-making based on real-world evidence will support product adoption and reimbursement approval.
  8. Strategic mergers and acquisitions will consolidate technology leadership and expand geographic reach.
  9. Integration of digital health tools and remote monitoring will support procedural guidance and post‑procedure follow-up.
  10. Emphasis on cost-effective solutions and value-based care will encourage healthcare providers to invest in innovative treatment options.

CHAPTER NO. 1: GENESIS OF THE MARKET
1.1 Market Prelude – Introduction & Scope
1.2 The Big Picture – Objectives & Vision
1.3 Strategic Edge – Unique Value Proposition
1.4 Stakeholder Compass – Key Beneficiaries
CHAPTER NO. 2: EXECUTIVE LENS
2.1 Pulse of the Product – Market Snapshot
2.2 Growth Arc – Revenue Projections (USD Million)
2.3. Premium Insights – Based on Primary Interviews
CHAPTER NO. 3: DRUG ELUTING BALLOON CATHETER MARKET FORCES & INDUSTRY PULSE
3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Product Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown
3.6 Price Trend Analysis
3.6.1 Regional Price Trend
3.6.2 Price Trend by Product
CHAPTER NO. 4: KEY INVESTMENT EPICENTER
4.1 Regional Goldmines – High-Growth Geographies
4.2 Component Frontiers – Lucrative Component Categories
4.3 Component Sweet Spots – Emerging Demand Segments
CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING
5.1 Momentum Metrics – Forecast & Growth Curves
5.2 Regional Revenue Footprint – Market Share Insights
5.3 Segmental Wealth Flow – Component & Component Revenue
CHAPTER NO. 6: TRADE & COMMERCE ANALYSIS
6.1. Import Analysis by Region
6.1.1. Global Drug Eluting Balloon Catheter Import Revenue By Region
6.2. Export Analysis by Region
6.2.1. Global Drug Eluting Balloon Catheter Export Revenue By Region
CHAPTER NO. 7: COMPETITION ANALYSIS
7.1. Company Market Share Analysis
7.1.1. Global Drug Eluting Balloon Catheter: Company Market Share
7.2. Global Drug Eluting Balloon Catheter Company Revenue Market Share
7.3. Strategic Developments
7.3.1. Acquisitions & Mergers
7.3.2. New Component Launch
7.3.3. Regional Expansion
7.4. Competitive Dashboard
7.5. Company Assessment Metrics, 2024
CHAPTER NO. 8: DRUG ELUTING BALLOON CATHETER MARKET – BY PRODUCT SEGMENT ANALYSIS
8.1. Drug Eluting Balloon Catheter Overview by Product Segment
8.1.1. Drug Eluting Balloon Catheter Revenue Share By Product
8.2. Coronary artery disease drug-eluting balloon catheters
8.3. Peripheral vascular disease drug-eluting balloon catheters
CHAPTER NO. 9: DRUG ELUTING BALLOON CATHETER MARKET – BY MATERIAL SEGMENT ANALYSIS
9.1. Drug Eluting Balloon Catheter Overview by Material Segment
9.1.1. Drug Eluting Balloon Catheter Revenue Share By Material
9.2. Polyurethane
9.3. Nylon
9.4. Others
CHAPTER NO. 10: DRUG ELUTING BALLOON CATHETER MARKET – BY END USE SEGMENT ANALYSIS
10.1. Drug Eluting Balloon Catheter Overview by End Use Segment
10.1.1. Drug Eluting Balloon Catheter Revenue Share By End Use
10.2. Hospitals and clinics
10.3. Ambulatory surgical centers
10.4. Catheterization laboratories
CHAPTER NO. 11: DRUG ELUTING BALLOON CATHETER MARKET – REGIONAL ANALYSIS
11.1. Drug Eluting Balloon Catheter Overview by Region Segment
11.1.1. Global Drug Eluting Balloon Catheter Revenue Share By Region
11.1.2. Regions
11.1.3. Global Drug Eluting Balloon Catheter Revenue By Region
11.1.4. Product
11.1.5. Global Drug Eluting Balloon Catheter Revenue By Product
11.1.6. Material
11.1.7. Global Drug Eluting Balloon Catheter Revenue By Material
11.1.8. End Use
11.1.9. Global Drug Eluting Balloon Catheter Revenue By End Use
CHAPTER NO. 12: NORTH AMERICA DRUG ELUTING BALLOON CATHETER MARKET – COUNTRY ANALYSIS
12.1. North America Drug Eluting Balloon Catheter Overview by Country Segment
12.1.1. North America Drug Eluting Balloon Catheter Revenue Share By Region
12.2. North America
12.2.1. North America Drug Eluting Balloon Catheter Revenue By Country
12.2.2. Product
12.2.3. North America Drug Eluting Balloon Catheter Revenue By Product
12.2.4. Material
12.2.5. North America Drug Eluting Balloon Catheter Revenue By Material
12.2.6. End Use
12.2.7. North America Drug Eluting Balloon Catheter Revenue By End Use
2.3. U.S.
12.4. Canada
12.5. Mexico
CHAPTER NO. 13: EUROPE DRUG ELUTING BALLOON CATHETER MARKET – COUNTRY ANALYSIS
13.1. Europe Drug Eluting Balloon Catheter Overview by Country Segment
13.1.1. Europe Drug Eluting Balloon Catheter Revenue Share By Region
13.2. Europe
13.2.1. Europe Drug Eluting Balloon Catheter Revenue By Country
13.2.2. Product
13.2.3. Europe Drug Eluting Balloon Catheter Revenue By Product
13.2.4. Material
13.2.5. Europe Drug Eluting Balloon Catheter Revenue By Material
13.2.6. End Use
13.2.7. Europe Drug Eluting Balloon Catheter Revenue By End Use
13.3. UK
13.4. France
13.5. Germany
13.6. Italy
13.7. Spain
13.8. Russia
13.9. Rest of Europe
CHAPTER NO. 14: ASIA PACIFIC DRUG ELUTING BALLOON CATHETER MARKET – COUNTRY ANALYSIS
14.1. Asia Pacific Drug Eluting Balloon Catheter Overview by Country Segment
14.1.1. Asia Pacific Drug Eluting Balloon Catheter Revenue Share By Region
14.2. Asia Pacific
14.2.1. Asia Pacific Drug Eluting Balloon Catheter Revenue By Country
14.2.2. Product
14.2.3. Asia Pacific Drug Eluting Balloon Catheter Revenue By Product
14.2.4. Material
14.2.5. Asia Pacific Drug Eluting Balloon Catheter Revenue By Material
14.2.5. End Use
14.2.7. Asia Pacific Drug Eluting Balloon Catheter Revenue By End Use
14.3. China
14.4. Japan
14.5. South Korea
14.6. India
14.7. Australia
14.8. Southeast Asia
14.9. Rest of Asia Pacific
CHAPTER NO. 15: LATIN AMERICA DRUG ELUTING BALLOON CATHETER MARKET – COUNTRY ANALYSIS
15.1. Latin America Drug Eluting Balloon Catheter Overview by Country Segment
15.1.1. Latin America Drug Eluting Balloon Catheter Revenue Share By Region
15.2. Latin America
15.2.1. Latin America Drug Eluting Balloon Catheter Revenue By Country
15.2.2. Product
15.2.3. Latin America Drug Eluting Balloon Catheter Revenue By Product
15.2.4. Material
15.2.5. Latin America Drug Eluting Balloon Catheter Revenue By Material
15.2.6. End Use
15.2.7. Latin America Drug Eluting Balloon Catheter Revenue By End Use
15.3. Brazil
15.4. Argentina
15.5. Rest of Latin America
CHAPTER NO. 16: MIDDLE EAST DRUG ELUTING BALLOON CATHETER MARKET – COUNTRY ANALYSIS
16.1. Middle East Drug Eluting Balloon Catheter Overview by Country Segment
16.1.1. Middle East Drug Eluting Balloon Catheter Revenue Share By Region
16.2. Middle East
16.2.1. Middle East Drug Eluting Balloon Catheter Revenue By Country
16.2.2. Product
16.2.3. Middle East Drug Eluting Balloon Catheter Revenue By Product
16.2.4. Material
16.2.5. Middle East Drug Eluting Balloon Catheter Revenue By Material
16.2.6. End Use
16.2.7. Middle East Drug Eluting Balloon Catheter Revenue By End Use
16.3. GCC Countries
16.4. Israel
16.5. Turkey
16.6. Rest of Middle East
CHAPTER NO. 17: AFRICA DRUG ELUTING BALLOON CATHETER MARKET – COUNTRY ANALYSIS
17.1. Africa Drug Eluting Balloon Catheter Overview by Country Segment
17.1.1. Africa Drug Eluting Balloon Catheter Revenue Share By Region
17.2. Africa
17.2.1. Africa Drug Eluting Balloon Catheter Revenue By Country
17.2.2. Product
17.2.3. Africa Drug Eluting Balloon Catheter Revenue By Product
17.2.4. Material
17.2.5. Africa Drug Eluting Balloon Catheter Revenue By Material
17.2.6. End Use
17.2.7. Africa Drug Eluting Balloon Catheter Revenue By End Use
17.3. South Africa
17.4. Egypt
17.5. Rest of Africa
CHAPTER NO. 18: COMPANY PROFILES
18.1. Aachen Resonance GmbH
18.1.1. Company Overview
18.1.2. Component Portfolio
18.1.3. Financial Overview
18.1.4. Recent Developments
18.1.5. Growth Strategy
18.1.6. SWOT Analysis
18.2. B. Braun
18.3. Becton, Dickinson and Company
18.4. Biosensors International
18.5. Biotronik AG
18.6. Boston Scientific Corporation
18.7. Eurocor GmbH
18.8. iVascular S.L.U.
18.9. Lepu Medical Technology(Beijing) Co. Ltd.
18.10. MedAlliance

Frequently Asked Questions:

What is the current size of the Drug Eluting Balloon Catheter Market?

The Drug Eluting Balloon Catheter Market reached USD 663.36 million in 2024.

What factors are driving the growth of the Drug Eluting Balloon Catheter Market?

Growth is driven by rising cardiovascular disease prevalence, demand for minimally invasive procedures, and continuous product innovation.

What are the key segments within the Drug Eluting Balloon Catheter Market?

The key segments include product (coronary and peripheral catheters), material (polyurethane, nylon, others), and end-use (hospitals, ambulatory centers, catheterization labs).

What are some challenges faced by the Drug Eluting Balloon Catheter Market?

Regulatory complexities, high initial device costs, and variable reimbursement policies are key challenges.

Who are the major players in the Drug Eluting Balloon Catheter Market?

Major players include Boston Scientific Corporation, Biotronik AG, B. Braun, Biosensors International, and Eurocor GmbH.

About Author

Shweta Bisht

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Gunakesh Parmar

Reviewed By
Gunakesh Parmar

Research Consultant

With over 15 years of dedicated experience in market research since 2009, specializes in delivering actionable insights from data.

View Profile

Ocular Drug Delivery Technologies Market

Published:
Report ID: 14127

Fish Oil Based Drugs Market

Published:
Report ID: 111617

Multiple Sclerosis Drugs Market

Published:
Report ID: 14271

Penicillin Drug Market

Published:
Report ID: 110208

Veterinary Anesthesia Drugs Market

Published:
Report ID: 110297

Generic Oncology Drugs Market

Published:
Report ID: 6393

Pulmonary Drug Delivery Devices Market

Published:
Report ID: 8314

Asthma And COPD Drugs Market

Published:
Report ID: 2348

Hypercholesterolemia Drugs Market

Published:
Report ID: 5717

Automated Insulin Delivery System Market

Published:
Report ID: 111962

Bacterial Conjunctivitis Market

Published:
Report ID: 7159

Advanced Wound Care Management Market

Published:
Report ID: 2599

Diabetic Ketoacidosis Treatment Market

Published:
Report ID: 72227

Fish Oil Based Drugs Market

Published:
Report ID: 111617

Patient Hygiene Aids Market

Published:
Report ID: 111668

Neuromorphic ASIC Market

Published:
Report ID: 111557

Blow-Fill-Seal Packaging Services in the Healthcare Market

Published:
Report ID: 111499

Companion Animal Health Market

Published:
Report ID: 4013

Human Rabies Treatment Market

Published:
Report ID: 7313

Acute Myeloid Leukemia (AML) Therapeutics Market

Published:
Report ID: 1267

Weight Checkers For Capsules And Tablets Market

Published:
Report ID: 111410

Purchase Options

The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing.
$4699

To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis and multi-location access, making it an excellent choice for organizations with distributed workforce.
$5699

The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc.’s research team. It is highly recommended for organizations seeking to execute short, customized research projects related to the scope of the purchased report.
$12699

Credence Staff 3

WILLIAM, North America

Support Staff at Credence Research

KEITH PHILLIPS, Europe

Lee - CR Sales Staff

LEE VALLANCE, Asia Pacific

Kieran Jameson

KIERAN JAMESON, Australia

Smallform of Sample request

Report delivery within 24 to 48 hours

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –


support

24/7 Research Support


– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN

Request Sample